Humacyte (NASDAQ:HUMA) Given Neutral Rating at Piper Sandler

Piper Sandler reaffirmed their neutral rating on shares of Humacyte (NASDAQ:HUMA) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $4.00 target price on the stock.

HUMA has been the topic of several other reports. HC Wainwright assumed coverage on shares of Humacyte in a research report on Monday, December 11th. They set a buy rating and a $6.00 price target on the stock. Benchmark reaffirmed a buy rating and set a $15.00 price target on shares of Humacyte in a research report on Monday.

Humacyte Stock Performance

NASDAQ HUMA opened at $3.11 on Tuesday. The company has a current ratio of 6.79, a quick ratio of 6.79 and a debt-to-equity ratio of 0.46. The firm’s fifty day moving average price is $3.55 and its two-hundred day moving average price is $2.98. Humacyte has a 1 year low of $1.96 and a 1 year high of $5.60. The firm has a market capitalization of $363.44 million, a P/E ratio of -2.91 and a beta of 1.53.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.01. During the same quarter in the prior year, the business earned ($0.21) EPS. As a group, research analysts anticipate that Humacyte will post -0.94 EPS for the current year.

Hedge Funds Weigh In On Humacyte

Several large investors have recently modified their holdings of the stock. UBS Asset Management Americas Inc. raised its position in shares of Humacyte by 17.3% in the second quarter. UBS Asset Management Americas Inc. now owns 15,947 shares of the company’s stock valued at $51,000 after purchasing an additional 2,347 shares during the period. Legal & General Group Plc raised its position in shares of Humacyte by 24.7% in the second quarter. Legal & General Group Plc now owns 16,970 shares of the company’s stock valued at $55,000 after purchasing an additional 3,364 shares during the period. Susquehanna International Group LLP increased its position in Humacyte by 16.2% during the first quarter. Susquehanna International Group LLP now owns 31,367 shares of the company’s stock worth $97,000 after acquiring an additional 4,372 shares during the period. UBS Group AG increased its position in Humacyte by 92.0% during the third quarter. UBS Group AG now owns 9,827 shares of the company’s stock worth $32,000 after acquiring an additional 4,710 shares during the period. Finally, Osaic Holdings Inc. increased its position in Humacyte by 16.3% during the second quarter. Osaic Holdings Inc. now owns 33,985 shares of the company’s stock worth $97,000 after acquiring an additional 4,775 shares during the period. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).